Citations

Showing 10 of 108162 citations.

Development of an international standard set of outcome measures for patients with atrial fibrillation: a report of the International Consortium for Health Outcomes Measurement (ICHOM) atrial fibrillation working group
Seligman, William , Das‐Gupta, Zofia , Jobi-Odeneye, Adedayo O. , Arbelo, Elena , Banerjee, Amitava , Caffrey-Armstrong, Bridget , Cehic, D. , Corbalán, Ramón , Collins, Michael , Dandamudi, Gopi, Dorairaj, Prabhakaran, Fay, Matthew , Gelder, Isabelle C. Van , Goto, Shinya , Granger, Christopher B. , Gyorgy, Bathory , Hendriks, Jeroen , Hills, Mellanie True , Hobbs, Richard , Koplan, Kate , Lane, Deirdre A. , Lewis, William R. , Lobban, Trudie , Moseley, S. Kelley, Camm, A. John , Granger, Christopher B , Arbelo, Elena , Banerjee, Amitava , Hobbs, F D Richard , Hendriks, Jeroen M , Lane, Deirdre A , Bollmann, Andreas , Collins, Michael , Dorairaj, Prabhakaran, Healey, Jeff S. , Huisman, Menno Volkert , Steinberg, Benjamin A. , McLeod, Christopher J. , Timmis, Adam , Guo, Yutao

Mayo Clinic

European Heart Journal | December 2, 2019 | Volume: 41 | Issue: 10 | Pages: 1132-1140

10.1093/eurheartj/ehz871 | PMID 31995195 Get It

Abstract Aims As health systems around the world increasingly look to measure and improve the value of care that they provide to patients, being able to measure the outcomes that matter most to patients is vital. To support the shift towards value-based health care in atrial fibrillation (AF), the International Consortium for Health Outcomes Measurement (ICHOM) assembled an international Working Group (WG) of 30 volunteers, including health professionals and patient representatives to develop a standardized minimum set of outcomes for benchmarking care delivery in clinical settings. Methods and results Using an online-modified Delphi process, outcomes important to patients and health professionals were selected and categorized into (i) long-term consequences of disease outcomes, (ii) complications of treatment outcomes, and (iii) patient-reported outcomes. The WG identified demographic and clinical variables for use as case-mix risk adjusters. These included baseline demographics, comorbidities, cognitive function, date of diagnosis, disease duration, medications prescribed and AF procedures, as well as smoking, body mass index (BMI), alcohol intake, and physical activity. Where appropriate, and for ease of implementation, standardization of outcomes and case-mix variables was achieved using ICD codes. The standard set underwent an open review process in which over 80% of patients surveyed agreed with the outcomes captured by the standard set. Conclusion Implementation of these consensus recommendations could help institutions to monitor, compare and improve the quality and delivery of chronic AF care. Their consistent definition and collection, using ICD codes where applicable, could also broaden the implementation of more patient-centric clinical outcomes research in AF.
Association of Longitudinal β-Amyloid Accumulation Determined by Positron Emission Tomography With Clinical and Cognitive Decline in Adults With Probable Lewy Body Dementia
Nedelská, Zuzana , Lesnick, Timothy G. , Przybelski, Scott A. , Lowe, Val J. , Kremers, Walter K. , Gunter, Jeffrey L. , Senjem, Matthew L. , Graff‐Radford, Jonathan , Ferman, Tanis J. , Fields, Julie A. , Petersen, Ronald C. , Jack, Clifford R. , Kantarci, Kejal , Jack, Clifford R , Nedelska, Zuzana , Senjem, Matthew L , Kantarci, Kejal , Ferman, Tanis J , Kremers, Walter K , Schwarz, Christopher G. , Boeve, Bradley F. , Knopman, David S.

Mayo Clinic

JAMA Network Open | December 2, 2019 | Volume: 2 | Issue: 12 | Pages: e1916439

10.1001/jamanetworkopen.2019.16439 | PMID 31790563 Get It

The immune landscape and response to immune checkpoint blockade therapy in lymphoma
Godfrey, James , Ansell, Stephen M. , Kline, Justin Paul

Mayo Clinic

Blood | December 2, 2019 | Volume: 135 | Issue: 8 | Pages: 523-533

10.1182/blood.2019000847 | PMID 31790142 Get It

Abstract The clinical development of effective cancer immunotherapies, along with advances in genomic analysis, has led to the identification of tumor environmental features that predict for sensitivity to immune checkpoint blockade therapy (CBT). Early-phase clinical trial results have demonstrated the remarkable effectiveness of CBT in specific lymphoma subtypes, including classical Hodgkin lymphoma and primary mediastinal B-cell lymphoma. Conversely, CBT has been relatively disappointing in follicular lymphoma and diffuse large B-cell lymphoma. These clinical observations, coupled with important scientific discoveries, have uncovered salient features of the lymphoma microenvironment that correlate with immunotherapy response in patients. For example, classical Hodgkin lymphoma is characterized by an inflammatory environment, genetic alterations that facilitate escape from immune attack, and sensitivity to PD-1 blockade therapy. On the other hand, for lymphomas in which measures of immune surveillance are lacking, including follicular lymphoma and most diffuse large B-cell lymphomas, anti-PD-1 therapy has been less effective. An improved understanding of the immune landscapes of these lymphomas is needed to define subsets that might benefit from CBT. In this article, we describe the immune environments associated with major B-cell lymphomas with an emphasis on the immune escape pathways orchestrated by these diseases. We also discuss how oncogenic alterations in lymphoma cells may affect the cellular composition of the immune environment and ultimately, vulnerability to CBT. Finally, we highlight key areas for future investigation, including the need for the development of biomarkers that predict for sensitivity to CBT in lymphoma patients.
Thyroid Disorders: A Webliography
Gerberi, Dana

Mayo Clinic

Journal of Consumer Health on the Internet | December 2, 2019 | Volume: 23 | Issue: 4 | Pages: 419-428

10.1080/15398285.2019.1681876 Get It

Intraoperative Irreversible Electroporation in Locally Advanced Pancreatic Cancer: A Guide for the Interventional Radiologist
Frey, G. , Padula, Carlos A. , Stauffer, John , Toskich, Beau , Frey, Gregory T, Toskich, Beau B. , A Stauffer, John

Mayo Clinic

Seminars in Interventional Radiology | December 2, 2019 | Volume: 36 | Issue: 05 | Pages: 386-391

10.1055/s-0039-1697640 | PMID 31798212 Get It

AbstractEfforts to improve mortality associated with locally advanced pancreatic cancer (LAPC) have shown minimal gains despite advances in surgical technique, systemic treatments, and radiation therapy. Locoregional therapy with ablation has not been routinely adopted due to the high risk of complications associated with thermal destruction of the pancreas. Irreversible electroporation (IRE) is an emerging, nonthermal, ablative technology that has demonstrated the ability to generate controlled ablation of LAPC while preserving pancreatic parenchymal integrity. IRE may be performed percutaneously or via laparotomy and will commonly involve multidisciplinary treatment teams. This article will describe the technical aspects of how multidisciplinary IRE is performed during laparotomy at a single tertiary care institution.
Ethanol Ablation of Neck Metastases from Differentiated Thyroid Carcinoma
Paz‐Fumagalli, Ricardo , Li, Xi , Smallridge, Robert C.

Mayo Clinic

Seminars in Interventional Radiology | December 2, 2019 | Volume: 36 | Issue: 05 | Pages: 381-385

10.1055/s-0039-1696651 | PMID 31798211 Get It

AbstractDifferentiated thyroid cancer often metastasizes to cervical lymph nodes, characteristically with slow growth rate and low-level aggressiveness. Cervical lymph node resection is the treatment of choice, but ethanol ablation offers a therapeutic option for patients with few nodes unresponsive to radioiodine therapy and who are poor surgical candidates. The ethanol ablation procedure is minimally invasive, guided sonographically, easily and safely repeated, and easily implemented with minimal technology and cost. Transient nerve injury is infrequent and virtually the only important complication. Current experience indicates that ethanol ablation has the safest therapeutic profile compared to surgery and thermal ablation, and the effectiveness is comparable to thermal ablation and approaches that of surgery. Well-designed clinical trials are lacking.
Comorbidities in vestibular migraine
Eggers, Scott D.Z. , Neff, Brian A., Shepard, Neil T., Staab, Jeffrey P. , Staab, Jeffrey P

Mayo Clinic

Journal of Vestibular Research | December 2, 2019 | Volume: 24 | Issue: 5-6 | Pages: 387-395

10.3233/ves-140525 | PMID 25564081 Get It

A growing body of clinical and epidemiological evidence supports a specific relationship between vestibular symptoms and migraine. Without a biomarker or complete understanding of pathophysiology, diagnosis of vestibular migraine (VM) currently depends upon symptoms in two dimensions: episodic vestibular symptoms temporally related to migraine symptoms. The Bárány Society and the International Headache Society have recently developed consensus diagnostic criteria. However, many issues remain unsettled, including the type, duration, and timing of vestibular symptoms related to headache that should be required for diagnosing VM. This paper focuses on the challenging third dimension of comorbidity, a frequent cause of diagnostic uncertainty that may confound clinical application and research validation of VM criteria. Several other neurotologic conditions occur more frequently in migraineurs than controls, including benign paroxysmal positional vertigo, Ménière's disease, and motion sickness. Patients with VM also have high rates of chronic subjective dizziness, which may be associated with anxious, introverted temperaments that can affect clinical presentation and treatment response. Broadly inclusive studies of well-characterized patients with other neurotologic and psychiatric comorbidities are needed to fully understand how vestibular symptoms and migraine interact in order to truly validate vestibular migraine, distill its essential features, define its boundaries, and characterize overlapping comorbidities.
The effect of galvanic vestibular stimulation on distortion product otoacoustic emissions
Cevette, Michael J. , Cocco, Daniela , Pradhan, Gaurav N. , Galea, Anna M., Wagner, Linsey S., Oakley, Sarah R., Smith, Benn E., Zapala, David A., Brookler, Kenneth H. , Pradhan, Gaurav N , Stepánek, Jan

Mayo Clinic

Journal of Vestibular Research | December 2, 2019 | Volume: 22 | Issue: 1 | Pages: 17-25

10.3233/ves-2012-0444 | PMID 22699149 Get It

Galvanic stimulation has long been used as a nonmechanical means of activating the vestibular apparatus through direct action on the vestibular nerve endings. This stimulation has been reported to be safe, but no studies have examined the potential changes in the corresponding cochlear receptors. The aim of the present study was to evaluate the effect of galvanic vestibular stimulation (GVS) on distortion product otoacoustic emissions (DPOAEs). Fourteen subjects underwent DPOAEs during several conditions of GVS. The DPOAEs ranged from ∼ 1 kHz to ∼ 8 kHz at 65/55 dB for f1/f2 and with an f2/f1 ratio of 1.2. The subjects were evaluated at 10 stimulation conditions that ranged from −2.0 mA to +2.0 mA for each frequency. Statistical analysis showed no significant differences in DPOAE amplitudes for all conditions with and without GVS. Results also showed no significant differences between DPOAE amplitudes before and after GVS. Multivariate analysis found subject variability in DPOAE amplitude, which was not thought to be GVS related. Results indicated that GVS produced neither temporary nor permanent changes in DPOAEs.
Clinical clues to a dizzying headache
Staab, Jeffrey P. , Staab, Jeffrey P

Mayo Clinic

Journal of Vestibular Research | December 2, 2019 | Volume: 21 | Issue: 6 | Pages: 331-340

10.3233/ves-2011-0426 | PMID 22348938 Get It

Recent years have witnessed an upsurge of interest in migraine as a cause of vestibular symptoms. Starting with 1970s case reports linking migraine to childhood vertigo, neurotologists worldwide have increasingly diagnosed migraine. Various syndromes of vestibular migraine (VM) have been described, diagnostic criteria proposed, epidemiologic data collected, and neurophysiologic models developed. Yet, the concept that migraine causes vestibular symptoms rests on a surprisingly thin research database. Current concepts of VM are based on expert opinion, not empirical data. No general consensus exists about the definition of VM. No studies have analyzed its essential features. Just one well-controlled medication trial has been published. No biomarkers are known. To stimulate more rigorous research, this paper poses three questions about clinical investigations into migraine and vestibular symptoms: What variables should be measured? What patients should be studied? How might clinical trials yield both clinically useful results and greater insights into pathophysiologic processes? Using these questions, the limits of current knowledge are explored. Applicable research methods from epidemiology to genetics are examined. Pilot data demonstrating pharmacologic and genetic dissection techniques are presented. Ambitious, but practical, near-term clinical research goals are enumerated, including rigorous validation of diagnostic criteria and development of empirically derived management guidelines.
Use of the Dynamic Visual Acuity Test as a screener for community-dwelling older adults who fall
Honaker, Julie A. , Shepard, Neil T.

Mayo Clinic

Journal of Vestibular Research | December 2, 2019 | Volume: 21 | Issue: 5 | Pages: 267-276

10.3233/ves-2011-0427 | PMID 22101297 Get It

Adequate function of the peripheral vestibular system, specifically the vestibulo-ocular reflex (VOR; a network of neural connections between the peripheral vestibular system and the extraocular muscles) is essential for maintaining stable vision during head movements. Decreased visual acuity resulting from an impaired peripheral vestibular system may impede balance and postural control and place an individual at risk of falling. Therefore, sensitive measures of the vestibular system are warranted to screen for the tendency to fall, alerting clinicians to recommend further risk of falling assessment and referral to a falling risk reduction program. Dynamic Visual Acuity (DVA) testing is a computerized VOR assessment method to evaluate the peripheral vestibular system during head movements; reduced visual acuity as documented with DVA testing may be sensitive to screen for falling risk. This study examined the sensitivity and specificity of the computerized DVA test with yaw plane head movements for identifying community-dwelling adults (58–78 years) who are prone to falling. A total of 16 older adults with a history of two or more unexplained falls in the previous twelve months and 16 age and gender matched controls without a history of falls in the previous twelve months participated. Computerized DVA with horizontal head movements at a fixed velocity of 120 deg/sec was measured and compared with the Dynamic Gait Index (DGI) a gold standard gait assessment measurement for identifying falling risk. Receiver operating characteristics (ROC) curve analysis and area under the ROC curve (AUC) were used to assess the sensitivity and specificity of the computerized DVA as a screening measure for falling risk as determined by the DGI. Results suggested a link between computerized DVA and the propensity to fall; DVA in the yaw plane was found to be a sensitive (92%) and accurate screening measure when using a cutoff logMAR value of > 0.25.